UPDATED Mar 09, 2024
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
DBVADBV Technologies | €0.58 | 5.5% | -58.6% | €136.5m | €1.81 | PS9.5x | E51.7% | n/a | ||
PCJAbeona Therapeutics | US$7.35 | 18.0% | 180.5% | US$197.4m | US$19.83 | PS55.3x | E55.4% | n/a | ||
2LBIovance Biotherapeutics | US$14.69 | -1.6% | 141.9% | US$4.4b | US$24.25 | PS3688.1x | E60.8% | n/a | ||
7UMUltimovacs | kr0.52 | -95.6% | -94.5% | kr275.2m | kr5.17 | PB1x | E60.6% | n/a | ||
45OOrgenesis | US$1.16 | 0% | -50.0% | US$34.9m | US$5.66 | PB1.3x | E142.2% | n/a | ||
9SOSolasia Pharma K.K | JP¥0.21 | 5.0% | -35.8% | JP¥6.4b | n/a | PS10.4x | E64.7% | n/a | ||
XUPBGenfit | €3.38 | 0% | n/a | €160.3m | €9.83 | PS5.5x | E52.3% | n/a | ||
XUPBGenfit | €3.14 | -1.3% | -20.3% | €160.3m | €9.13 | PS5.5x | E52.3% | n/a | ||
LWBMesoblast | AU$0.16 | 7.2% | -73.1% | AU$319.7m | n/a | PS28.3x | E65.5% | n/a | ||
FYBFormycon | €47.60 | -1.9% | -34.7% | €763.4m | €103.33 | PS11.1x | E72.1% | n/a | ||
2L9Blueprint Medicines | US$85.50 | -5.5% | 117.1% | US$5.7b | US$90.02 | PS22.7x | E66.3% | n/a | ||
69OAelis Farma | €13.15 | -2.2% | -6.9% | €176.6m | €20.86 | PS18x | E29.2% | n/a | ||
1AEAargenx | €354.00 | 0% | 6.0% | €21.1b | €430.63 | PS18.2x | E56.8% | n/a | ||
EH3AAmarin | US$0.80 | -13.6% | -44.6% | US$379.1m | n/a | PS1.2x | E51.2% | n/a | ||
IKAPAurinia Pharmaceuticals | US$4.88 | -6.4% | -39.7% | US$785.3m | US$9.49 | PS4.5x | E53.7% | n/a | ||
AKPAnika Therapeutics | US$23.00 | 2.7% | -8.7% | US$372.2m | US$25.03 | PS2.3x | E65.6% | n/a | ||
49BABeiGene | US$148.00 | -0.7% | -26.7% | US$16.6b | US$252.38 | PS6.7x | E57.4% | n/a | ||
I4PIntercept Pharmaceuticals | US$17.52 | -0.8% | 14.9% | US$794.7m | US$17.52 | PS2.5x | E42.4% | n/a | ||
49BBeiGene | US$11.20 | -1.8% | -28.7% | US$16.6b | US$19.10 | PS6.7x | E57.4% | n/a | ||
EXKExact Sciences | US$55.87 | 5.4% | -5.2% | US$10.9b | US$82.34 | PS4.4x | E61.5% | n/a | ||
DYF1Dynavax Technologies | US$11.48 | 0.3% | 27.5% | US$1.7b | US$21.55 | PS7.4x | E41.6% | n/a | ||
MYDMyriad Genetics | US$26.72 | 0% | -2.2% | US$1.3b | US$33.52 | PS2x | E53.5% | n/a | ||
1YGMendus | kr0.018 | -34.2% | -85.8% | kr422.5m | n/a | PS14.3x | E61.5% | n/a |